An independent committee expresses concern on US efficacy data for AstraZeneca's COVID-19 vaccine; cases of COVID-19 are on the rise in over half of states; wildfire smoke is associated with a significant spike in pediatric respiratory care visits.
As reported by Reuters, the Data Safety Monitoring Board (DSMB), an independent committee overseeing the US trial on the COVID-19 vaccine manufactured by AstraZeneca, has expressed concern that the company may have released outdated information on the trial that would create an incomplete view of the efficacy data. In data unveiled yesterday, AstraZeneca said their vaccine was 79% effective in preventing the virus, with no safety concerns reported. This came after controversy surrounding the vaccine’s unproven links to blood clots in Europe that caused several countries to suspend use.
According to data from Johns Hopkins University, the US 7-day average of daily new cases of COVID-19 are up by at least 5% in 27 states, with a 1% increase nationwide reported after months of rapidly declining case numbers. Reported by CNBC, cases include those of the COVID-19 variant first discovered in the United Kingdom, B117, that some health officials speculate may be the cause of significant case increases in states such as Michigan that reported a 50% increase compared with last week. As vaccination rates rise to about 2.5 million shots per day, testing for COVID-19 has dropped dramatically, suggesting that data may not reflect the true number of cases across the country.
A study published today in Pediatrics found that respiratory care visits among children were associated most prominently with wildfire smoke than other sources of airborne fine particles, even when wildfires were less severe. Reported by STAT, a 10-unit increase of PM2.5, airborne particles less than 2.5 mcm wide from wildfire smoke was linked with a 30% spike in admissions compared with 3.7% from nonsmoke sources. Reasons for pediatric respiratory care visits included asthma, difficulty breathing, respiratory distress, wheezing, and cough.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More